Later this month, a new panel of outside experts appointed by the FDA will make recommendations on whether seven peptides including some of the most popular injectables like TB-500, BPC-157 and MOTs-C should be added to a list that gives compounding pharmacies the greenlight to, again, manufacture the products
Among the highlights: a manuscript detailing the clinical trials of BPC-157 as a treatment for ulcerative colitis
Crossing strategies are: (1) bypassing intranasal route, (2) lipid modifications (Dihexa), (3) active transporters (insulin, transferrin), (4) vehicles like nanoparticles or exosomes
Quality of reporting in systematic reviews of adverse events: systematic review
If you want to administer 10 units, pull the plunger back to the 10-unit mark
PMID: 23949208 Clark KL, et al